Clinical Trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Study acronym: SABR-SYNC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-06; most recent amendment 2025-12-24.
Status change: Not Yet Recruiting → Recruiting 2023-10-10
Trial Details
NCT Number NCT05717166
Lead Sponsor David Palma
Conditions Metastatic Tumor
Enrollment 180 participants
Start Date 2023-10-06
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2025-12-31